Bivalent bispecific antibody - DIABETES FREE
Alternative Names: Bivalent BsAb - DIABETES FREELatest Information Update: 31 Oct 2025
At a glance
- Originator DIABETES FREE
- Class Bispecific antibodies; Immunotherapies
- Mechanism of Action B cell inhibitors; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 30 Sep 2025 Preclinical trials in Autoimmune disorders in USA (Parenteral) (DIABETES FREE pipeline; September 2025)
- 30 Sep 2025 DIABETES FREE plans first-in-human clinical trial for Autoimmune disorders (Parenteral) in Q1 2026